Agency / Source: Greenphire, LLC

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Greenphire Partners with Lyft to Support Clinical Trial Patient Retention and Access - Integration expands the industry-leading clinical participant payment software to enable study coordinators to book and manage rides seamlessly within one application - lyft.com / Greenphire.com
Greenphire Partners with Lyft to Support Clinical Trial Patient Retention and Access

 

PRZOOM - /newswire/ - King of Prussia, PA, United States, 2018/06/19 - Integration expands the industry-leading clinical participant payment software to enable study coordinators to book and manage rides seamlessly within one application - lyft.com / Greenphire.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Greenphire, the global leader in financial software for clinical trials, today announced it has partnered with Lyft (lyft.com), to deliver a seamless experience for site coordinators to book a ride and execute a reimbursement or stipend for clinical trial participants within its industry-leading ClinCard solution. With this integration, the clinical research community will have one seamless application to eliminate both the financial and logistical hurdles that impact clinical trial retention.

“Expense management and ground transportation are critical to participant retention. However, patient and site needs are not equal. That is why we have designed the only application that allows a study coordinator to order a car, reimburse for a ride, and provide a stipend all within one software,” said Jim Murphy, CEO, Greenphire.

Greenphire’s ClinCard is the industry standard in participant payment automation, facilitating more than six million reimbursements to over one million clinical trial participants around the world. The new offering is the only solution that brings both ride and payment automation within one central application, delivering a better experience for both sites and participants.

“Lyft is committed to improving accessibility for patients in need of better transportation options,” said Gyre Renwick, Vice President of Lyft Business. “This opportunity to extend our services with Greenphire allows us to work together to create the best experience for clinical trial participants and help to eliminate any complications for patients getting to and from their appointments.”

Centralizing the participant retention budget within ClinCard eliminates siloes and optimizes financial visibility and predictability for sponsors. It also allows sponsors to make clinical trial participation easier for patients, without adding an administrative burden for site coordinators.

About Greenphire

Greenphire (greenphire.com) is the global leader in clinical trial payment software. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Greenphire, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Greenphire Partners with Lyft to Support Clinical Trial Patient Retention and Access

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Lyft | Greenphire
Contact: Press Office - Greenphire.com 
215-609-4378 / 215-609-4640 sales[.]greenphire.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greenphire, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Greenphire, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today